ENVERIC BIOSCIENCES INC (ENVB) Fundamental Analysis & Valuation

NASDAQ:ENVB • US29405E5050

Current stock price

1.99 USD
+0.04 (+2.05%)
Last:

This ENVB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ENVB Profitability Analysis

1.1 Basic Checks

  • In the past year ENVB has reported negative net income.
  • ENVB had a negative operating cash flow in the past year.
  • In the past 5 years ENVB always reported negative net income.
  • In the past 5 years ENVB always reported negative operating cash flow.
ENVB Yearly Net Income VS EBIT VS OCF VS FCFENVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • ENVB has a worse Return On Assets (-257.81%) than 90.10% of its industry peers.
  • ENVB has a Return On Equity of -325.39%. This is in the lower half of the industry: ENVB underperforms 78.13% of its industry peers.
Industry RankSector Rank
ROA -257.81%
ROE -325.39%
ROIC N/A
ROA(3y)-270.94%
ROA(5y)-232.69%
ROE(3y)-540.58%
ROE(5y)-408.37%
ROIC(3y)N/A
ROIC(5y)N/A
ENVB Yearly ROA, ROE, ROICENVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • ENVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENVB Yearly Profit, Operating, Gross MarginsENVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

6

2. ENVB Health Analysis

2.1 Basic Checks

  • ENVB has more shares outstanding than it did 1 year ago.
  • ENVB has more shares outstanding than it did 5 years ago.
  • ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENVB Yearly Shares OutstandingENVB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K 40K 50K
ENVB Yearly Total Debt VS Total AssetsENVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -40.84, we must say that ENVB is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ENVB (-40.84) is worse than 90.10% of its industry peers.
  • There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -40.84
ROIC/WACCN/A
WACCN/A
ENVB Yearly LT Debt VS Equity VS FCFENVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 4.60 indicates that ENVB has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.60, ENVB is doing good in the industry, outperforming 64.06% of the companies in the same industry.
  • A Quick Ratio of 4.60 indicates that ENVB has no problem at all paying its short term obligations.
  • The Quick ratio of ENVB (4.60) is better than 65.63% of its industry peers.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
ENVB Yearly Current Assets VS Current LiabilitesENVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. ENVB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.83% over the past year.
EPS 1Y (TTM)79.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ENVB will show a very strong growth in Earnings Per Share. The EPS will grow by 41.17% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.66%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENVB Yearly Revenue VS EstimatesENVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2027 2028 2029 2030 2031 50M 100M
ENVB Yearly EPS VS EstimatesENVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2021 2022 2023 2024 2025 2026 -5K -10K -15K -20K -25K

1

4. ENVB Valuation Analysis

4.1 Price/Earnings Ratio

  • ENVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENVB Price Earnings VS Forward Price EarningsENVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENVB Per share dataENVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

  • ENVB's earnings are expected to grow with 41.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.17%
EPS Next 3YN/A

0

5. ENVB Dividend Analysis

5.1 Amount

  • ENVB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ENVB Fundamentals: All Metrics, Ratios and Statistics

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (4/8/2026, 1:37:36 PM)

1.99

+0.04 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)05-12
Inst Owners8.52%
Inst Owner Change0%
Ins Owners2.88%
Ins Owner Change0%
Market Cap2.77M
Revenue(TTM)N/A
Net Income(TTM)-11.25M
Analysts82.86
Price Target122.4 (6050.75%)
Short Float %7.12%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-255.6
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-5.52
FCFYN/A
OCF(TTM)-5.52
OCFYN/A
SpS0
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -257.81%
ROE -325.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-270.94%
ROA(5y)-232.69%
ROE(3y)-540.58%
ROE(5y)-408.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z -40.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.91%
EPS Next Y99.66%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.03%
EBIT Next 3Y2.98%
EBIT Next 5Y33.29%
FCF growth 1Y51.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.5%
OCF growth 3YN/A
OCF growth 5YN/A

ENVERIC BIOSCIENCES INC / ENVB Fundamental Analysis FAQ

What is the fundamental rating for ENVB stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENVB.


Can you provide the valuation status for ENVERIC BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to ENVERIC BIOSCIENCES INC (ENVB). This can be considered as Overvalued.


What is the profitability of ENVB stock?

ENVERIC BIOSCIENCES INC (ENVB) has a profitability rating of 0 / 10.